Skip to main content

Advertisement

Table 2 Per-protocol secondary endpoint analysis of treatment responses in cases with Plasmodium falciparum or Plasmodium vivax for PCR-uncorrected malaria

From: Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated malaria in Papua New Guinea

  AL DHA-PPQ Total P-value
P. falciparum assessed at day 28, n 110 138 248  
 Adequate clinical and parasitological response, n (%) [95% CI] 108 (98.2) [92.9–99.7] 138 (100) [96.6–100] 246 (99.2) − 0.28
 Early treatment failure, % 0 0 0
 Late clinical failure, % 0.9 0 0.4
 Late parasitological failure, % 0.9 0 0.4
P. falciparum assessed at day 42, n 106 135 241  
 Adequate clinical and parasitological response, n (%) [95% CI] 102 (96.2) [90.07–98.8] 132 (97.8) [93.2–99.4] 234 (97.1) 0.48
 Early treatment failure, % 0 0 0
 Late clinical failure, % 0 0 0
 Late parasitological failure, % 3.8 2.2 2.9
P. vivax assessed day 28, n 23 41 64  
 Adequate clinical and parasitological response, n (%) [95% CI] 20 (87.0) [65.3–96.6] 41 (100) [89.3–100] 61 (95.3) 0.06
 Early treatment failure, % 0 0 0
 Late clinical failure, % 4.3 0 1.6
 Late parasitological failure, % 8.7 0 3.1
P. vivax assessed day 42, n 19 39 58  
 Adequate clinical and parasitological response, n (%) [95% CI] 13 (68.4) [43.5–86.4] 34 (87.2) [71.8–95.2] 47 (81.03) 0.23
 Early treatment failure, % 0 0 0
 Late clinical failure, % 10.5 5.1 6.9
 Late parasitological failure, % 21.1 7.7 5.3